supporting you at every stage
Growing a tiny human can be exhausting, but your diabetes management doesn’t need to be!
The Dexcom ONE+ Continuous Glucose Monitoring (CGM) System is our most accurate CGM system1,* giving people the confidence to make informed treatment decisions.
Anyone over 2 years of age living with type 1, type 2, or gestational diabetes where self-monitoring of blood glucose (SMBG) is indicated may benefit from CGM.
From 1st October 2024, Pharmac is providing access to funded CGM products and automated insulin delivery (AID) systems for all New Zealanders with type 1 diabetes and other forms of diabetes similar in impact to type 1 diabetes.†
† Dexcom is fully funded under special authority criteria – a prescription item payment may be charged.
What is Continuous Glucose Monitoring (CGM)?
Continuous Glucose Monitoring (CGM) is a tool that measures glucose levels 24/7 using a sensor under the skin. The Dexcom ONE+ system includes a one-touch sensor applicator and a mobile app‡ that shows real-time and past glucose data. It wirelessly sends readings to devices like smartphones, smartwatches, or an optional receiver.‡ This system provides real-time glucose readings with zero fingerpricks§ and can alert you if your glucose levels are too high or too low.
Display devices sold separately.‡
The Benefits of Dexcom CGM
Tight glycaemic management is especially important when you are expecting. Always know your glucose levels, where they’re headed and how fast with just a quick glance at your smartphone or watch,‡ so you can take action sooner.
Smart and accurate2,7
Along with Dexcom G7, Dexcom ONE+ is our most accurate CGM system.2,7
Customisable alerts
Dexcom ONE+ offers the essential Dexcom alerts to meet your needs. With customisable high and low alerts, you know when your glucose levels fall outside of an adjustable and preset high and low glucose range.
Easy to get started
Dexcom ONE+ is designed for a smooth and easy start. Our self-onboarding gets you set up quickly. The intuitive in-app onboarding guides users through the set-up steps. In a few clicks, you are on.
Improved quality of life3
Live life with peace of mind knowing that Dexcom ONE+’s accuracy has got your back.
Increase time in range||,4-6
Dexcom rt-CGM systems are clinically proven to increase time in range.||,4-6 The more time you spend in range, the better you may feel and more you can do.
Reduce hyperglycaemia and improve HbA1c||,4-6
Proven to reduce hyperglycaemia and improve HbA1c.||,4-6
Take control of your diabetes management
Congratulations on your pregnancy! You've got this. It's important to maintain tight glycaemic management during pregnancy but hormones can make glucose management a challenge. Pregnancy is challenging enough!
Let Dexcom assist you in taking care of your glucose management so you can focus on what's important to you.
For women living with type 1 diabetes and other forms of diabetes similar in impact to type 1 diabetes, Pharmac funding for CGM is available.† Speak to your Healthcare Team about accessing the Dexcom CGM system. If you don't qualify for funding, visit our online shop.
† Dexcom is fully funded under special authority criteria – a prescription item payment may be charged.
Ready to Take the Next Step?
Eligible for funded CGM?
Dexcom CGMs are fully funded for pregnant women and women planning to become pregnant with type 1 diabetes. To explore funded CGM, we encourage you to reach out to your Diabetes Healthcare Team.
Not eligible for funding?
You can easily shop via NZMS Diabetes (a Dexcom company) our online store by clicking the button below!
Still have questions about Dexcom CGM?
Speak to one of our product specialists.
* As compared to Dexcom G6 System. † Eligibility criteria apply. Visit pharmac.govt.nz for more details. ‡ Smart devices sold separately. For a list of compatible devices, visit www.dexcom.com/compatibility. § If your glucose alerts and readings from the Dexcom CGM do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. || These studies did not include pregnant women.
References: 1 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7. 2 Garg SK, et al. Diabetes Technol Ther. 2022;24(6):373-80. 3 Lind M, et al. Diabetes Care. 2021;44(1):141-149. 4 Beck RW, et al. JAMA. 2017;317(4):371-378. 5 Beck RW et al. Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7. Polsky S, et al. Diabetes Technol Ther. 2024;26(5):307-12.